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Abstract
Background—Multiple primary cancers account for ~16% of all incident cancers in the U.S.. 
While genome-wide association studies (GWAS) have identified many common genetic variants 
associated with various cancer sites, no study has examined the association of these genetic 
variants with risk of multiple primary cancers (MPC).
Methods—As part of the NHGRI Population Architecture using Genomics and Epidemiology 
(PAGE) study, we used data from the Multiethnic Cohort and Women’s Health Initiative. Incident 
MPC (IMPC) cases (n=1,385) were defined as participants diagnosed with >1 incident cancers 
after cohort entry. Participants diagnosed with only one incident cancer after cohort entry with 
follow-up equal to or longer than IMPC cases served as controls (single-index cancer controls; n= 
9,626). Fixed-effects meta-analyses of unconditional logistic regression analyses were used to 
evaluate the association between cancer risk variants and IMPC risk. To account for multiple 
comparisons, we used the false positive report probability (FPRP) to determine statistical 
significance.
Results—A nicotine dependence-associated and lung cancer variant, CHRNA3 rs578776 
(OR=1.16, 95% CI=1.05–1.26; p=0.004) and two breast cancer variants, EMBP1 rs11249433 and 
TOX3 rs3803662 (OR=1.16, 95% CI=1.04–1.28; p=0.005 and OR=1.13, 95% CI=1.03–1.23; 
p=0.006) were significantly associated with risk of IMPC. The associations for rs578776 and 
rs11249433 remained (p<0.05) after removing subjects who had lung or breast cancers, 
respectively (p-values≤0.046). These associations did not show significant heterogeneity by 
smoking status (p-heterogeneity≥0.53).
Conclusions—Our study has identified rs578776 and rs11249433 as risk variants for IMPC.
Impact—These findings may help to identify genetic regions associated with IMPC risk.
Keywords
Multiple Primary Cancer; Cancer Genetic Risk Variants
Introduction
In the past 50 years, the 5-year relative survival rate for all cancers has dramatically 
increased from 49% to 67%(1). As a result, the number of cancer survivors is growing by 
2% per year(2). Compared to the general population, cancer survivors are at a greater risk 
for a number of comorbidities, including the occurrence of subsequent primary cancers(3), 
which is one of the leading causes of death for long-term cancer survivors (>5-years)(4, 5). 
In 2002, Surveillance Epidemiology and End Results (SEER) data indicated that ~16% of all 
new cancers in the U.S. were second or higher-order primary cancers(1). Risk factors for 
developing multiple primary cancers (MPC) include younger age at index (first) cancer, 
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treatment modality for the index cancer, shared etiological factors (e.g. smoking) and 
genetic susceptibility(3).
Genome-wide association studies (GWAS) have identified several hundred genetic variants 
associated with various types of cancers(6). Pleiotropy, defined as when a single variant is 
associated with more than one phenotype, has been identified for some of these cancer risk 
loci(7, 8). For instance, variants in the chromosome 8q24 locus have been associated with 
risk of prostate, breast, colorectal and other cancers(8) and those near the telomerase reverse 
transcriptase gene (TERT) have been associated with many cancer sites(9–14), including 
lung(15–17), estrogen-receptor negative breast(18), ovary(19) and pancreatic(20) cancers. 
Given that some cancer risk variants are associated with more than one cancer site, it is 
possible that they may also be associated with risk of developing MPC. Identification of 
such risk variants may elucidate common cancer etiologies and pathways, improve our 
understanding of treatment-related effects or identify populations at risk for developing 
multiple cancers.
With the exception of familial cancer syndromes, the literature examining genetic variants 
and risk of MPC is sparse, and is usually limited to risk after a specific index cancer site. 
Furthermore, prior studies are rarely based on prospective data and there has been no 
systematic investigation of the relationship between common cancer susceptibility variants 
and MPC risk. Thus, we utilized prospective data from the Population Architecture using 
Genomics and Epidemiology (PAGE) study to investigate the associations of 188 cancer 
risk variants with risk of incident MPC.
Materials and Methods
Study Populations
The PAGE study(21) was initiated in 2008 by the National Human Genome Research 
Institute (NHGRI). Two PAGE studies in collaboration with NHGRI and the coordinating 
center(21) participated in this analysis, the Multiethnic Cohort (MEC)(22) and the Women’s 
Health Initiative (WHI)(23). Informed consent was obtained from all study participants. This 
investigation was approved by each study’s respective Institutional Review Boards.
Briefly, the MEC was initiated in 1993 to investigate the impact of dietary and 
environmental factors on major chronic diseases, particularly cancer, in ethnically diverse 
populations in Hawai’i and California(22). The study recruited 96,810 men and 118,441 
women aged 45 to 75 years between 1993 and 1996. MEC subjects recontacted mostly from 
1995 to 2001 for blood collection included incident cases with breast, prostate, or colorectal 
cancers, as well as a random sample of cohort participants to serve as controls in genomic 
nested case-control studies (participation rate 72% and 63%, respectively). The median 
interval between diagnosis and blood draw was 14 months (interquartile range, 10–19 
months). From 2001 to 2006 blood was also collected, prospectively, without regard for 
cancer diagnosis, from willing cohort participants (participation rate 43%). Incident cancers 
are identified through annual linkage to the Hawai’i Tumor Registry, Los Angeles County 
Cancer Surveillance Program and the California Cancer Registry. All three registries are 
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members of SEER(24). At the time of case selection for this analysis, follow-up was 
complete as to December 31, 2007
The Women’s Health Initiative (WHI) is a long-term health study that recruited 161,808 
post-menopausal women aged 50 to 79 years between 1992 and 1998 at 40 clinical centers 
throughout the U.S. WHI comprises a Clinical Trial (CT) arm, an Observational Study (OS) 
arm, and several extension studies, which are studies with continued follow-up of 
consenting participants from the original two study arms. The details of WHI have been 
previously described(23, 25), and are available online(26). Blood draw was taken at time of 
study recruitment on all study participants. During the follow-up period of January 1, 1992 
to September 30, 2013, incident cancers were identified among participants in the OS and 
CT arm. Potential cancer status was identified from self-reported and/or hospital record data 
and confirmation of status was determined through review of the participant’s medical 
records and pathology reports by trained cancer coders.
Case and Control Definitions
Details regarding the study design and case-control definitions are presented in 
Supplementary Table 1. All subjects for this analysis were cancer-free at baseline and had to 
have developed at least 1 cancer during study follow-up. MPC cases were defined as those 
who were diagnosed with more than one invasive primary cancer (non-melanoma skin 
cancers were excluded) during study follow-up(27), and are referred herein as incident 
multiple primary cancer (IMPC) cases. Controls were defined as subjects who developed 
only one invasive primary cancer during study follow-up and are referred to as incident 
single-index cancer (ISC) controls. In order to test the association of cancer risk variants 
with risk of subsequent cancers, cancer-free controls were not used in this analysis. In the 
MEC, which identifies cancer cases by linkage to SEER registries, IMPC cases could have a 
subsequent primary cancer of the same site, provided that the subsequent cancer met the 
SEER definition for same site MPCs (e.g., a subsequent breast cancer following a first breast 
cancer defined as primary given the following conditions: 1) contralateral breast cancer that 
did not result from metastases, 2) breast cancer of a different histologic cell type, or 3) 
breast cancer 5+ years after initial diagnosis)(27). No second primaries were allowed for 
prostate cancer, leukemia and non-Hodgkin’s lymphoma, also based on SEER rules. In the 
WHI, which adjudicated cancer cases by medical record review, it was not possible to 
systematically determine whether the cancer of the same site was a subsequent primary 
cancer or metastases. Thus, a repeat diagnosis of the same cancer site during follow-up was 
not counted as IMPC in WHI. IMPC cases for each study were frequency matched to all 
eligible ISC controls by age of index cancer diagnosis (within 5-year intervals), length of 
follow-up (where controls had follow-up time that was equal to or greater than that of the 
cases), race and sex. This analysis included a total of 1,385 IMPC cases and 9,626 ISC 
controls. In preliminary analyses, we had additionally matched for first cancer site. As the 
findings were similar, we matched only on age, sex, and race/ethnicity to increase our 
sample size and adjusted for first cancer in the statistical model.
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SNP Selection and Genotyping
A total of 188 cancer risk variants associated with 18 cancers and nicotine dependence 
(nicotine dependence SNPs were considered herein as cancer risk variants given that 
smoking is a major risk factor for several cancer sites)(28) were identified from the NHGRI 
catalog of GWAS studies(6) as of January 2010, followed by a review of the original reports 
and the fine mapping literature(12, 14–17, 20, 29–84). The risk allele for each SNP was 
determined based on the prior literature and was defined as the allele associated with an 
increased risk of cancer in the first GWAS report.
Genotyping for the 188 cancer variants (175 SNPs in WHI and 156 SNPs in MEC; 143 
SNPs with overlap) was performed using the TaqMan OpenArray platform (MEC) and 
Illumina BeadXpress (WHI). To control for population stratification, a panel of 128 ancestry 
informative markers(85) were genotyped. Principal components analysis(86) was performed 
and the main principal components were included in the regression model to adjust for 
genetic ancestry in each study.
Standard quality-assurance and quality-control measures were applied to ensure genotyping 
quality(21). Samples and SNPs were included based on call rates (≥90%), concordance of 
blinded replicates (>98%), and no clear departure from Hardy-Weinberg equilibrium 
(p>0.001).
Statistical Analysis
For each study, we tested the association between each SNP and risk of IMPC using 
unconditional logistic regression. SNPs were coded additively, with 0, 1, 2 referring to the 
number of risk alleles. Models were adjusted for age at diagnosis for the index cancer 
(continuous), sex (MEC only), study design (WHI only: CT vs. OS), the most significant 
principal components (PC) of genetic ancestry (to account for race/ethnicity [five PCs for 
the MEC and three PCs for WHI]), and index cancer site (17 categories), stage (local, 
regional, distant) and diagnosis year (to account for treatment cohort effects). We adjusted 
for index cancer site and stage to account for differences in cancer survival.
The regression estimates were combined across studies using inverse-variance weighted, 
fixed-effect meta-analysis as implemented in METAL (http://www.sph.umich.edu/csg/
abecasis/Metal/). We calculated the cross-study and cross-race heterogeneity p-values based 
on Cochran’s Q statistic. Stratified analysis by race/ethnicity were conducted for SNP 
associations with p<0.05. To account for the multiple testing of 188 SNPs, we used the false 
positive report probability (FPRP) introduced by Wacholder et al.(87). We set a stringent 
FPRP threshold of 0.20 and assigned a prior probability range of 0.01–0.10 to detect an OR 
of 1.2 or 0.83. Variants that were found to be significantly associated with IMPC after 
correction for multiple comparisons were further investigated in sensitivity analyses in 
which subjects with the cancer site (either as index cancer or IMPC) corresponding to the 
variant’s first known GWAS association were removed, as well as after adjusting for or 
stratifying by smoking status, obtained by self-report at baseline.
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The main characteristics of the 1,385 IMPC cases and 9,626 ISC controls are presented in 
Table 1. Subjects were of six different ethnic/racial populations: European American, 
African American, Hispanic, Asian, Pacific Islander, and Native American. Forty-three 
percent of subjects were European American and 59% were female (the MEC ascertained 
both sexes, while WHI ascertained only women). The most common index cancer sites were 
prostate and breast for the MEC and colorectal and breast for WHI. In both studies, among 
all IMPC cases, breast cancer was the most common incident second cancer (for the MEC, 
n=164 and for WHI, n=133). The distribution of index and subsequent incident cancers by 
study is presented in Table 2 and Supplemental Table 2 (which includes latency intervals 
between cancer sites). The most common index and subsequent cancer combination in the 
MEC study was an index breast and subsequent breast cancers and in the WHI study index 
endometrial and subsequent breast cancers. Less common cancers were collapsed as ‘other;’ 
the enumeration of these cancer sites can be found in Supplemental Table 3 (WHI) and 
Supplemental Table 4 (MEC). There were 115 MEC IMPC cases and 15 WHI IMPC cases 
with 3 or more cancers (Supplemental Table 5).
We examined a total of 188 cancer risk variants (Table 3 for associations with p<0.05 and 
Supplementary Table 6 for associations with p≥0.05). Prostate and breast cancer risk 
variants represented the greatest proportions of variants (28% and 15%, respectively). 
Among the 188 SNPs, 12 were found to be associated with risk of IMPC at p<0.05 (Table 
3). These 12 associations were with three prostate cancer variants, three lung cancer 
variants, two breast cancer variants, one pancreatic cancer variant, one melanoma variant, 
one thyroid variant and one colorectal variant. These associations were not found to be 
heterogeneous by study or race/ethnicity (p>0.05) (Table 3 and Supplemental Table 7).
After correction for multiple comparisons, we found that the associations of CHRNA3 
rs578776, EMBP1 rs11249433 and TOX3 rs3803662 with IMPC remained statistically 
significant at a FPRP threshold of 0.20 and a prior probability of 0.01 (Table 4). The 
CHRNA3 rs578776 risk allele “C” previously associated with nicotine dependence and lung 
cancer, was associated with an increased risk of IMPC (OR=1.15, 95% CI=1.05–1.26; 
p=0.004) (Table 2). The risk allele “C” for the breast cancer variant EMBP1 rs11249433 
was also associated with an increased risk of IMPC (OR=1.16, 95% CI=1.04–1.28; 
p=0.005). The risk allele “T” for the breast cancer variant TOX3 rs11249433, located at 
16q12.1, was also associated with an increased risk of IMPC (OR=1.13, 95% CI=1.03–1.23; 
p=0.006).
When removing from the analysis all subjects with lung cancer for the CHRNA3 variant and 
with breast cancer for the EMBP1 and TOX3 variants, either as index cancer or IMPC, the 
associations for CHRNA3 rs578776 and EMBP1 rs11249433 remained significant 
(p’s≤0.046) (Table 5). The association for rs3803662 had a similar OR as its main effects; 
however, the association did not quite reach statistically significant (OR=1.13; p=0.005 vs 
OR=1.11; p=0.064, respectively).
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Because smoking is a risk factor for many cancers, we additionally adjusted our models for 
smoking status and pack-years and found similar associations (data not shown). In our 
analyses stratified by smoking status, no heterogeneity in the effects of the genetic variants 
was detected between never and ever smokers (p-heterogeneity≥0.53) (Table 5). Due to a 
limitation in sample size, we were unable to restrict this analysis to cancers that are 
unrelated to smoking.
Discussion
To our knowledge, this is the first study to examine the association of cancer risk variants 
with risk of IMPC. We tested 188 established cancer risk variants among 1,385 IMPC cases 
and 9,626 ISC controls and found that the lung cancer/nicotine dependence risk allele “C” of 
CHRNA3 rs578776 and the breast cancer risk alleles “C” of EMBP1 rs11249433 and “T” of 
TOX3 of rs3803662 were associated with an increased risk of IMPC. The associations for 
rs578776 and rs11249433 remained after accounting for multiple hypothesis testing, were 
not restricted to participants with the cancer previously associated with those variants, and 
were consistent with regard to smoking status.
The 15q25.1 region includes the CHRNA5-CHRNA3-CHRNB4 cluster of cholinergic 
nicotine receptor subunit genes. Variants within this region have been associated with 
increased risk of lung cancer primarily due to their relationships with smoking behavior and 
nicotine dependence(15, 81, 82, 88). In addition, risk variants in the CHRNA5-CHRNA3-
CHRNB4 region have been positively associated with chronic obstructive pulmonary 
disease(89), serum albumin levels(90), pulmonary function(91) and childhood obesity-
related traits in Hispanics(92). In our study, we found that both rs578776 and rs8042374, 
which are in high LD in whites and Asians (CEU: r2=0.83, YRI: r2=0.16, CHB+JPT: 
r2=0.72), were positively associated with risk of multiple primary cancers when compared to 
those with only one incident cancer. Only the association with rs578776 remained 
significant after correction for multiple testing. Smoking is an established risk factor for at 
least 10 different cancer sites(28); therefore, a reasonable explanation for the association of 
these variants with IMPC would be the result of their known association with smoking. 
However, when stratifying by smoking status, we found that the association was somewhat 
stronger, albeit not significantly (p-heterogeneity by smoking≥0.47), in never smokers 
(OR=1.21; p=0.01) than in ever smokers (OR=1.13; p=0.05). This association in never 
smokers is unexpected and could be due to chance. Further study of this risk variant with 
IMPC in never smokers is warranted.
The rs11249433 variant is located in the pericentromeric region at 1p11.2 and within the 
embigin pseudogene, EMBP1. This SNP maps near many other pseudogenes in a SNP desert 
region. EMBP1 rs11249433 was originally found to be associated with breast cancer (p=7x 
10−10)(69). Additional studies found that rs11249433 was specifically associated with ER-
positive breast cancer(69, 93) and lower grade breast tumors(93), two characteristics that are 
associated with improved breast cancer survival(94). It is possible that the association for 
rs11249433 with increased risk of MPC may be related to survivorship such that a longer 
survival after breast cancer diagnosis may lead to a higher likelihood of developing a 
subsequent primary cancer. When removing subjects with breast cancer as the index cancer 
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or an IMPC from our analysis, the association of rs11249433 with IMPC persisted, although 
not as significant, suggesting that this association was not exclusively due to a better breast 
cancer survival. This SNP may play a role in increased overall cancer survival or risk of 
cancer development. The closest located genes to rs11249433 are a transmembrane coding 
gene, NOTCH2 and highly paralogous low-affinity Fc gamma receptor family 1B gene, 
FCGR1B. SNPs in NOTCH2 have been associated with Type-2 diabetes(95), a condition 
that has been associated with an increased risk of breast, colorectal, pancreatic, liver, urinary 
tract and endometrial cancers(96, 97). In addition, a study that investigated the expression of 
five genes within 1 Mb of rs11249433 found an increased expression of NOTCH2 in 
patients with ER-positive breast cancer without TP53 mutations compared to those with 
TP53 mutations(98). NOTCH2 receptors are involved in regulation of cell communication, 
proliferation, differentiation and death(99), processes that are all influential in cancer 
development.
The rs3803662 variant is located at 16q12.1 in the Cancer Susceptibility Candidate 16 gene, 
CASC16, which is an RNA gene. TOX3 and LOC643714 are other genes located close to 
this polymorphism. This variant has been previously associated with breast cancer (p-
value=6x10−19)(65), with slightly stronger associations in ER-positive breast cancer than 
ER-negative disease(100). A prior study found that the risk allele for rs3803662 is correlated 
with lower mRNA expression of TOX3 in ER-positive tumors(101). Increased TOX3 mRNA 
expression has been previously found to be predictive of breast cancer metastases(102) and 
lower overall survival among breast cancer patients(101). It is possible that the association 
for rs3803662 with increased risk of MPC may be related to survival from breast cancer. 
When removing subjects with breast cancer, the association was not quite statistically 
significant, suggesting that this association may be due to the risk variants prior association 
with breast cancer.
This study had a number of strengths, including the prospective design which allowed us to 
focus on incident cancers and minimize survival bias, while investigating multiple primary 
cancer risk in an adult population. We also had a long follow-up period to assess subsequent 
cancers (MEC: 14 years and WHI: 19 years), a large sample size, and well-characterized 
study populations enabling adjustment for multiple potential confounders. Study limitations 
include limited power to detect effects for rare SNPs and the lack of detailed information on 
treatment, especially, on radiation therapy, a known risk factor for multiple primaries(103). 
In the MEC, where information on first course of cancer therapy was available, similar 
results were observed after adjusting for radiation treatment (yes/no). In addition, our meta-
analyzed findings did not change when adjusting for index cancer stage, suggesting that our 
findings are not strongly dependent on the treatment received, since treatment is relatively 
well standardized by stage. Our study oversampled the more common cancer sites as a result 
of the blood collection design in the earlier years of the MEC. Also, for WHI, the study 
undersampled breast and colorectal cancer cases to be genotyped for the PAGE analysis. 
Therefore, the more common cancer sites, with the exception of lung cancer, may have been 
overrepresented in the MEC and endometrial cancer was overrepresented in WHI. 
Additionally, cases with subsequent primary cancers of the same site were not available in 
the WHI study and were, thus, underrepresented in that study.
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In conclusion, our findings, if reproduced, may contribute toward identifying common 
cancer etiologic pathways, common treatment-related effects, or populations at risk for 
developing more than one cancer. We found the cancer risk variant rs578776 in CHRNA3 to 
be associated with occurrence of multiple primary cancers. Our analysis suggests that the 
associations for TOX3 rs3803662 may have been driven by the variants known association 
with breast cancer. However, the association for EMBP1 rs11249433 and CHRNA3 
rs578776 appears to be independent of their known cancer association. These findings 
should be confirmed in other study populations.
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Refer to Web version on PubMed Central for supplementary material.
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Table 1










Age of index cancer; Mean (SD) 68.3 (7.8) 68.0 (8.3) 70.1 (7.0) 69.7 (9.0)
Age of 2nd cancer; Mean (SD) 72.6 (8.0) NA 74.2 (7.3) NA
Follow-up time, years; Mean (SD) 9.4 (3.3) 13.7 (1.9) 9.6 (3.7) 12.7 (2.3)
Sex; n (%)
 Male 549 (56.9) 3930 (56.4)
 Female 416 (43.1) 3039 (43.6) 420 (100) 2657 (100)
Race/ethnicity; n (%)
 European American 254 (26.3) 1534 (22.0) 372 (88.6) 2088 (78.6)
 African American 235 (24.4) 1419 (20.4) 37 (8.8) 412 (15.5)
 Hispanic 194 (20.1) 1581 (22.7) 6 (1.4) 96 (3.6)
 Asian 232 (24.0) 2045 (29.3)
4 (0.95)b 58 (2.2)b
 Pacific Islander 50 (5.2) 390 (5.6)
 Indian/Native American NA NA 1 (0.24) 3 (0.11)
Smoking status
 Never 352 (36.9) 2843 (41.4) 174 (41.4) 1292 (48.6)
 Former 421 (44.1) 3064 (44.6) 200 (47.6) 1123 (42.3)
 Current 182 (19.1) 959 (14.0) 42 (10.0) 212 (8.0)
 missing, n 10 103 4 30
Pack-yearsa; Mean (SD) 21.9 (17.0) 18.0 (15.7) 15.3 (22.0) 11.0 (19.1)
 missing, n 31 260 14 90
Index Cancer site
 Breast 265 (27.5) 1970 (28.3) 82 (19.5) 906 (34.1)
 Prostate 278 (28.8) 2906 (41.7) NA NA
 Colorectal 164 (17.0) 987 (14.2) 67 (16.0) 433 (16.3)
 Lung 24 (2.5) 175 (2.5) 43 (10.2) 291 (11.0)
 Otherc 234 (24.2) 931 (13.4) 228 (54.3) 1027 (38.7)
Secondary Cancer site
 Breast 164 (17.0) NA 133 (31.7) NA
 Prostate 111 (11.5) NA NA NA
 Colorectal 158 (16.4) NA 49 (11.7) NA
 Lung 120 (12.4) NA 65 (15.5) NA
 Otherc 412 (42.7) NA 173 (41.2) NA
Stage of index cancer, n (%)
 Localized 683 (70.8) 5153 (73.9) 288 (68.6) 1651 (61.1)
 Regional 215 (22.3) 1346 (19.3) 86 (20.1) 640 (24.1)
 Distant 67 (6.9) 470 (6.7) 46 (11.0) 366 (13.8)
Diagnosis year for index cancer, Mean (SD) 1998 (3.4) 2000 (3.7) 2002 (3.5) 2003 (3.7)
































Diagnosis year for second cancer, Mean (SD) 2002 (3.2) NA 2006 (3.7) NA
a
Pack-years for ever smokers only.
b
Counts for Asian and Pacific Islanders
c
The four most common other cancer sites include bladder, endometrium, leukemia, melanoma and non-Hodgkin’s lymphoma, enumeration for 
these sites can be found in Table 2.
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